THY1 and liver cancer: Chen et al. [33] also suggested that molecules which inhibited the signal axis of CD90-integrin-mTOR/AMPK-CD133, including OSU-CG5 and other inhibitors, maybe served as potential novel cancer therapeutic targets in liver cancer.